Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Clinical trial NCT03268954 · COMPLETED

Trial details

NCT number: NCT03268954
Sponsor: Takeda
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Myelodysplastic Syndrome Leukemia, Myelomonocytic, Chronic Leukemia, Myeloid, Acute

Start date: 2017-11-28
Primary completion: 2021-05-28
Enrollment: 454

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.